HF2906

Psilocybin therapeutic use program established; protections for registered patients, designated cultivators, registered facilitators, and health care practitioners established; rulemaking authorized; civil actions authorized; fees established; advisory committee established; criminal penalties provided; and money appropriated.
Legislative Session 94 (2025-2026)

Related bill: SF3971

AI Generated Summary

Purpose of the Bill

The bill aims to create a regulated program in Minnesota for the therapeutic use of psilocybin, a psychoactive compound found in certain mushrooms. This program is intended for individuals above the age of 21 with qualifying medical conditions, offering a legal framework for accessing psilocybin in a safe and therapeutic manner.

Main Provisions

  • Psilocybin Therapeutic Use Program: Establishment of a program under the Minnesota Department of Health for the administration and use of psilocybin through supervised sessions, addressing patient safety and harm reduction.
  • Eligibility and Enrollment: Individuals must be over 21, have a qualifying medical condition, and pass a health screening to enroll in the program starting January 1, 2027.
  • Designation and Cultivation: Registered patients can personally cultivate psilocybin or designate someone to cultivate on their behalf. Specific rules govern the amount and safety protocols of cultivation.
  • Facilitation and Supervision: Trained registered facilitators will oversee psilocybin administration sessions and are required to lead preparation and integration sessions.
  • Regulation and Rulemaking: The Health and Agriculture Commissioners will set rules concerning qualifying conditions, cultivation limits, and facilitator qualifications.

Significant Changes to Existing Law

  • Legal Protections: The bill includes protections against civil and criminal liabilities for participants, facilitators, and public employees associated with the program. It also restricts law enforcement from accessing registry data.
  • Employment and Housing Protections: Protects registered patients and facilitators from discrimination in employment and housing based solely on their participation in the program.
  • Advisory Committee: Formation of a Psychedelic Medicine Advisory Committee to guide the program's development and ensure ongoing evaluation.

Relevant Terms

psilocybin, therapeutic use, registered facilitators, designated cultivators, harm reduction, patient safety, advisory committee, cultivation, eligibility criteria, health screening, rulemaking, legal protections, discrimination in housing and employment.

Bill text versions

Showing the most recent version. There are  3  total versions. You must be logged in  to view additional bill text versions.

Past committee meetings

You must be logged in  to view 1  past legislative committee meetings.

Actions

DateChamberWhereTypeNameCommittee Name
March 27, 2025HouseActionIntroduction and first reading, referred toHealth Finance and Policy
April 01, 2025HouseActionAuthor added
February 25, 2026HouseActionAuthor added
March 12, 2026HouseActionAuthors added
March 16, 2026HouseActionCommittee report, to adopt as amended and re-refer toCommerce Finance and Policy
Showing the 5  most recent stages. This bill has 7  stages in total. Log in to view all stages

Meeting documents

You must be logged in  to view legislative committee meeting documents.

Citations

You must be logged in  to view citations.

Progress through the legislative process

17%
In Committee

Sponsors

You must be logged in  to view sponsors.

Loading…